异基因骨髓与G-CSF动员干细胞移植后免疫细胞重建动力学预测生存
基于BMT CTN 0201多中心随机研究410例患者数据,评估异基因移植后免疫重建的临床价值。G-PB移植受者T细胞重建更快,1个月CD4+和3个月CD8+ T细胞快速重建预测更多慢性GVHD但更好生存;BM受者3个月经典树突状细胞较高预测更好生存。
要点
- G-PB移植受者T细胞重建快于BM受者,3个月naive CD4+及TREC阳性CD4+/CD8+ T细胞更多。
- G-PB受者1个月CD4+和3个月CD8+ T细胞快速重建预测更多慢性GVHD但更好生存。
- BM受者3个月经典树突状细胞较高预测更好生存。
核心结论
- 早期T细胞重建测量是G-PB受者长期生存和GVHD治疗反应的预测性细胞生物标志物,而BM受者更稳健的DC重建预测更好生存。
研究设计与样本
- 多中心随机研究BMT CTN 0201(NCT00075816),比较无关供者骨髓(BM)与G-CSF动员外周血干细胞(G-PB)移植。
- 纳入410例有移植后流式细胞术免疫细胞亚群测量的患者。
主要发现
- G-PB受者T细胞重建快于BM受者,包括3个月时更多naive CD4+ T细胞及TREC阳性CD4+和CD8+ T细胞。
- G-PB受者1个月CD4+和naive CD4+ T细胞及3个月CD8+ T细胞快速重建预测更多慢性GVHD但更好生存;BM受者未见T细胞数量与GVHD或生存的一致关联。
- BM受者3个月血液经典树突状细胞(cDC)数量较高预测更好生存。
- 体外CMV肽刺激细胞因子分泌功能T细胞免疫在BM与G-PB受者间相似,但急性GVHD抑制免疫重建的程度因移植物来源而异。
- 有2-4级急性GVHD史的BM受者(非G-PB受者)3个月时B细胞、浆细胞样树突状细胞和cDC数量较低。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The clinical utility of monitoring immune reconstitution after allotransplant was evaluated using data from Blood and Marrow Transplant Clinical Trials Network BMT CTN 0201 (NCT00075816), a multicenter randomized study of unrelated donor bone marrow (BM) vs granulocyte colony-stimulating factor (G-CSF)-mobilized blood stem cell (G-PB) grafts. Among 410 patients with posttransplant flow cytometry measurements of immune cell subsets, recipients of G-PB grafts had faster T-cell reconstitution than BM recipients, including more naive CD4+ T cells and T-cell receptor excision circle-positive CD4+ and CD8+ T cells at 3 months, consistent with better thymic function. Faster reconstitution of CD4+ T cells and naive CD4+ T cells at 1 month and CD8+ T cells at 3 months predicted more chronic graft-versus-host disease (GVHD) but better survival in G-PB recipients, but consistent associations of T-cell amounts with GVHD or survival were not seen in BM recipients. In contrast, a higher number of classical dendritic cells (cDCs) in blood samples at 3 months predicted better survival in BM recipients. Functional T-cell immunity measured in vitro by cytokine secretion in response to stimulation with cytomegalovirus peptides was similar when comparing blood samples from BM and G-PB recipients, but the degree to which acute GVHD suppressed immune reconstitution varied according to graft source. BM, but not G-PB, recipients with a history of grades 2-4 acute GVHD had lower numbers of B cells, plasmacytoid dendritic cells, and cDCs at 3 months. Thus, early measurements of T-cell reconstitution are predictive cellular biomarkers for long-term survival and response to GVHD therapy in G-PB recipients, whereas more robust DC reconstitution predicted better survival in BM recipients.
引用
- Waller EK, Logan BR, Fei M, et al. Kinetics of immune cell reconstitution predict survival in allogeneic bone marrow and G-CSF-mobilized stem cell transplantation. Blood Adv. 2019. PMID: 31345792. doi:10.1182/bloodadvances.2018029892
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。